Cingulate (CING) Capital Expenditures (2021 - 2025)
Cingulate's (CING) quarterly Capital Expenditures came in at $156213.0 in Q4 2025, up 776.52% YoY from $17822.0 in Q4 2024, and up 776.52% on a QoQ basis from $17822.0 in Q4 2024.
Cingulate (CING) Capital Expenditures (2021 - 2025) Analysis & Trends
Cingulate (CING) has 5 years of Capital Expenditures data on file, last reported at $156213.0 in Q4 2025.
- Quarterly Capital Expenditures rose 776.52% year-over-year to $156213.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $105865.0 (up 239.75% YoY) and the FY2025 annual result came in at $162138.0, up 420.34% from the prior year.
- Capital Expenditures rose to $156213.0 in Q4 2025, from $17822.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $186960.0 in Q4 2023 to a low of -$207032.0 in Q3 2024.
- A 5-year average of $60329.9 and a median of $51802.0 in 2021 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 13886100.0% in 2024, down 90.47% in 2024.
- Tracing CING's Capital Expenditures over 5 years: stood at $175001.0 in 2021, then dropped by 18.27% to $143020.0 in 2022, then surged by 30.72% to $186960.0 in 2023, then slumped by 90.47% to $17822.0 in 2024, then jumped by 776.52% to $156213.0 in 2025.
- The last three Capital Expenditures figures came in at $156213.0 (Q4 2025), $17822.0 (Q4 2024), and -$207032.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 251.02 Mn |
| 10 | Cingulate | 72.52 Mn | 72.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 156,213.00 |
| Dec 31, 2025 | 156,213.00 |
| Dec 31, 2024 | 17,822.00 |
| Dec 31, 2024 | 17,822.00 |
| Sep 30, 2024 | -207,032.00 |
| Sep 30, 2024 | -207,032.00 |
| Jun 30, 2024 | 138,862.00 |
| Jun 30, 2024 | 138,862.00 |
| Mar 31, 2024 | 81,508.00 |
| Mar 31, 2024 | 81,508.00 |
| Dec 31, 2023 | 186,960.00 |
| Dec 31, 2023 | 186,960.00 |
| Jun 30, 2023 | 1.00 |
| Jun 30, 2023 | 1.00 |
| Mar 31, 2023 | 37,135.00 |
| Mar 31, 2023 | 37,135.00 |
| Dec 31, 2022 | 143,020.00 |
| Dec 31, 2022 | 143,020.00 |
| Mar 31, 2022 | 10,400.00 |
| Mar 31, 2022 | 10,400.00 |